Verano Holdings (VRNO) Retained Earnings (2024 - 2026)
Verano Holdings (VRNO) posted quarterly Retained Earnings of $1.7 billion for Q4 2025, up 322.73% year-over-year from $412.9 million in Q4 2024, and up 322.73% quarter-over-quarter from -$783.6 million in Q4 2024.
Verano Holdings (VRNO) Retained Earnings (2024 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Retained Earnings for 2 consecutive years, with $1.7 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 322.73% year-over-year to $1.7 billion; the TTM figure through Dec 2025 stood at $1.7 billion (up 322.73% YoY), while the FY2025 annual figure was $1.7 billion, up 322.73% from the prior year.
- Retained Earnings climbed to $1.7 billion in Q4 2025 per VRNO's latest filing, from -$783.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $1.7 billion in Q4 2025 and bottomed at -$783.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 3.75 Bn |
| 10 | Verano Holdings | 440.28 Mn | 355.08 Mn | 99.70 Mn | 1.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.75 Bn |
| Mar 31, 2026 | 1.75 Bn |
| Dec 31, 2025 | 1.75 Bn |
| Dec 31, 2024 | -783.61 Mn |